Track Altimmune, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Altimmune, Inc. ALT · Stock Open Altimmune, Inc. in new tab

1.65 USD
EPS
-0.71
P/B
0.72
ROE
-33.17
Beta
0.15
Target Price
16.67 USD
Altimmune, Inc. logo

Altimmune, Inc.

🧾 Earnings Recap – Q3 2026

Altimmune fell 16.6% after earnings, despite management’s positive framing. The transcript offers no new financial or clinical setback; the likely source of disappointment is the long wait for the pivotal PERFORMA readout, expected in 2029, with enrollment still ramping and ex-U.S. sites yet to activate.

  • PERFORMA Phase 3 is screening and dosing patients; the majority of planned U.S. sites are active, while ex-U.S. sites are expected to activate over the coming months.
  • The company anticipates PERFORMA’s 52-week data readout in 2029, leaving a lengthy timeline to a key MASH milestone.
  • Management said new 48-week IMPACT data highlighted antifibrotic activity; the study was published in *The Lancet* this week.
  • RECLAIM Phase 2 data in alcohol use disorder were presented as a late-breaking oral presentation; an FDA end-of-Phase 2 meeting is scheduled for next month.
  • Management cited estimates that 55%–94% of alcohol-related liver disease patients also meet criteria for alcohol use disorder, supporting its rationale for developing pemvidutide across both indications.
📅
Loading chart...
Key Metrics
Earnings dateMarch 3, 2027
EPS-0.71
Book Value2.28
Price to Book0.72
Debt/Equity7.89
% Insiders0.721%
Growth
Revenue Growth4.20%
Estimates
Forward P/E-2.40
Forward EPS-0.69
Target Mean Price16.67

DCF valuation

Model fair value for Altimmune, Inc. (ALT)
Result
Sign in to run the valuation for ALT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus Strong buy · mean target 16.67 USD (low 11.00, high 26.00) · as of 14 Nov 2026
Low 11.00
Mean 16.67
High 26.00
Price 1.65
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Altimmune, Inc. Logo Altimmune, Inc. Analysis (ALT)

United States Health Care Official Website Stock

Is Altimmune, Inc. a good investment? Altimmune, Inc. (ALT) is currently trading at 1.65 USD. Market analysts have a consensus price target of 16.67 USD. This suggests a potential upside from current levels.

Earnings Schedule: Altimmune, Inc. is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -0.69.

Investor FAQ

Does Altimmune, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Altimmune, Inc.?

Altimmune, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -0.71.

Company Profile

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Exchange Ticker
MEX (Mexico) ALT1.MX
FRA (Germany) 3G0.F
NMS (United States) ALT
LSE (United Kingdom) 0A4C.L
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2017
582.00 USD
Feb. 3, 2017 291.0000
Feb. 3, 2017 291.0033
Stock Splits
Split Date Split Ratio to 1
Sept. 14, 2018 1:30
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion